Merck's third quarter performance exhibited significant resilience in the face of SINGULAIR U.S. generic competition, with strong contributions from key products like JANUVIA and vaccines worldwide. However, guidance for 2013 acknowledged potential revenue headwinds, including the impending loss of SINGULAIR exclusivity in major European markets. While there are positive developments in the R&D pipeline, the company maintained a cautious stance on the upcoming year, hinting at expected challenges which might exert modest pressure on the stock in the near term.

[-1]